Trials / Completed
CompletedNCT03939702
Pharmacokinetic and Metabolism of [14^C] BMS-986177 in Healthy Male Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- Male
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
This is an ADME study. Human radiolabeled mass balance studies are performed as part of drug development to obtain information about the absorption, distribution, metabolism, and excretion (ADME) of a study treatment. The goals of human ADME studies include the assessment of absorption, distribution, routes and rates of excretion, mass balance, and metabolite profile and identification.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986177 | An orally administered anticoagulant to prevent and treat thromboembolic events |
Timeline
- Start date
- 2019-05-02
- Primary completion
- 2019-07-11
- Completion
- 2019-07-11
- First posted
- 2019-05-07
- Last updated
- 2019-10-04
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03939702. Inclusion in this directory is not an endorsement.